Wednesday 22nd November 2023
SRUK asks the Chancellor to consider the impact of changes to disability benefits on people with scleroderma and we renew our call for more support with energy bills for those that need it most.
Tuesday 21st November 2023
Ahead of the Chancellor's Autumn Statement we are calling on the government to expand its Cost of Living Payment criteria to include people living with Raynaud’s Phenomenon.
Thursday 22nd June 2023
SRUK Calls for greater investment in rare rheumatic disease training as survey finds Rheumatologists can struggle due to lack of education and resource
Thursday 16th March 2023
SRUK says the government plans for energy bills offer "short-term respite" - with longer-term solutions still needed.
Wednesday 8th March 2023
Ahead of the Chancellor’s Spring Budget and statement on 15th March we are delighted that Shadow Business Minister and MP for Feltham and Heston, Seema Malhotra, has joined our campaign to keep heating affordable for those living with Raynaud’s. SRUK is calling for government action after finding that many people with Raynaud’s, who typically rely on their heating to prevent painful attacks, are struggling with the high cost of energy.
Wednesday 1st February 2023
SRUK calls on public to write to their MP to help keep heating affordable for people with Raynaud's
Thursday 17th November 2022
Scleroderma and Raynaud’s UK (SRUK) has expressed its disappointment that people with Raynaud’s have been ignored once again by the government.
Tuesday 15th November 2022
“My Raynaud’s has definitely gotten worse this year. I used to have an attack a couple of times a week, particularly if I was outside in the cold, but now it happens every day, even in my own house.”
Monday 7th November 2022
SRUK Survey highlights the devastating impact of the cost-of-living crisis and high energy bills for people with Raynaud's.
Friday 4th November 2022
The Rare Autoimmune Rheumatic Disease Alliance (RAIRDA) which SRUK is a member of, has released a report highlighting ‘alarming disparities in the quality of care and treatment’ received by people living with rare autoimmune rheumatic diseases (RAIRDs).
